A new study has found that a ledipasvir–sofosbuvir combination is safe and effective for older individuals with genotype 1 hepatitis C virus (HCV) infection.
A new study has found that a ledipasvir–sofosbuvir combination is safe and effective for older individuals with genotype 1 hepatitis C virus (HCV) infection. Researchers analyzed sustained virological response at 12 weeks and monitored adverse events, comparing a sample of nearly 2,300 patients aged 65 years and older with a group younger than 65 years. At 12 weeks, 97% of the younger patients and 98% of those aged 65 years and older achieved sustained virological response. The most common adverse events were headache and fatigue. The findings are published in Hepatology.
I'm 67 years old & today I just finished 168 days of Sofosbuvir / Ledisbovir , plus 84 days Ribavirin.
I struggled with the Ribavirin side effects but just managed to stay on the full dose of 1200mg.
The last 4 weeks of treatment I suffered a lot of joint & muscle pain.
Also feeling fatigued most days.
Now it's a wait for SVR 4 & SVR 12 & SVR 24
HCV Genotype 1a
2003 Relapsed Peg Interferon / Ribavirin
Pre treatment VL 2,000,000
ALT 65, AST 42, ALP 111, GGT 56
Treatment -24 weeks - Sof , Led with 12 weeks Riba.
4 weeks VL <12 Detected ALP 89 , GGT 21 , ALT 17 , AST14
12 weeks VL Undetected ALP 96, GGT 22, ALT 20, AST 20
24 weeks VL Undetected ALP 83, GGT 20, ALT 21, AST 14
EOT 6th April 2016
SVR 5 weeks VL Undetected ALP 81, GGT 31, ALT 22, AST 20